Develops skin substitutes for wound care and sports medicine.
Jun 2026Revenue $457M/yrExpenses $493M/yr
No trend
Figures by year
When will Organogenesis Holdings be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $457M and expenses $493M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $564M | $519M | $44.7M |
| Dec 2024 | $482M | $483M | −$1.28M |
| Dec 2023 | $433M | $421M | $12.5M |
| Dec 2022 | $451M | $429M | $22.3M |
| Dec 2021 | $467M | $395M | $72.2M |
| Dec 2020 | $338M | $312M | $26.7M |
| Dec 2019 | $261M | $291M | −$29.9M |
| Dec 2018 | $193M | $245M | −$51.6M |
| Dec 2017 | $199M | $204M | −$5.49M |
| Dec 2016 | $139M | $148M | −$8.78M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.